Eli Lilly to buy Boston biotech Kelonia for $3.25 billion
It's the latest in a string of big-money moves the Indianapolis-based pharma giant has made locally.
- Eli Lilly agrees to buy cancer biotech Kelonia for up to $7 billion Boston Globe —
- Eli Lilly Announces $7 Billion Deal. What It Means for the Stock. Barrons —
- Eli Lilly Stock Falls as It Closes in on a $2 Billion Deal. Here’s Why. Barrons —
- Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion CNBC —